AZNAstraZenecaRunning, no new patients
Volrustomig Priming Regimens Exploratory Phase II Platform Study
Non-small Cell Lung Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 194 (final count)
- Started
- Aug 27, 2024
- Main results expected
- Jul 30, 2027
- Fully finished
- Jul 30, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
Measured over: From screening (Days -28 to Day -1) up to 2 year 10 months
Confirmed Objective Response rate (ORR)
Measured over: Up to 2 year 10 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06448754 · record last updated 2026-09-29 · checked 2026-11-09 15:47 UTC